In a Phase 2 study, researchers found that rontalizumab was a more effective treatment in patients with systemic lupus erythematosus who had an interferon signature metric score lower than 1.
In a Phase 2 study, researchers found that rontalizumab was a more effective treatment in patients with systemic lupus erythematosus who had an interferon signature metric score lower than 1.